IGM BIOSCIENCES INC

NASDAQ: IGMS (IGM Biosciences, Inc.)

Last update: 24 Jun, 7:50PM

1.18

0.02 (1.72%)

Previous Close 1.16
Open 1.18
Volume 101,704
Avg. Volume (3M) 176,220
Market Cap 70,935,816
Price / Sales 30.83
Price / Book 117.27
52 Weeks Range
0.920 (-22%) — 22.50 (1806%)
Earnings Date 12 Aug 2025 - 18 Aug 2025
Operating Margin (TTM) -6,217.44%
Diluted EPS (TTM) -3.27
Quarterly Revenue Growth (YOY) 0.40%
Total Debt/Equity (MRQ) 6,298.14%
Current Ratio (MRQ) 5.71
Operating Cash Flow (TTM) -143.10 M
Levered Free Cash Flow (TTM) -75.65 M
Return on Assets (TTM) -36.78%
Return on Equity (TTM) -245.59%

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Bearish Bearish
Biotechnology (Global) Bearish Bearish
Stock IGM Biosciences, Inc. Bearish Bearish

AIStockmoo Score

0.1
Analyst Consensus -3.5
Insider Activity 1.5
Price Volatility -2.0
Technical Moving Averages 2.5
Technical Oscillators 2.0
Average 0.10

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
IGMS 71 M - - 117.27
CORT 7 B - 59.69 11.07
MDGL 7 B - - 9.46
TGTX 6 B - 146.88 24.57
SLNO 4 B - - 18.80
ACLX 4 B - - 8.88

IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.

Sector Healthcare
Industry Biotechnology
Investment Style Small Growth
% Held by Insiders 37.57%
% Held by Institutions 47.53%
52 Weeks Range
0.920 (-22%) — 22.50 (1806%)
Median 1.00 (-15.25%)
Total 1 Hold
Firm Date Target Price Call Price @ Call
Truist Securities 11 Jun 2025 1.00 (-15.25%) Hold 1.27
Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
BAKER BROS. ADVISORS LP 1.12 - 1,906 2,135
BEHRENS M KATHLEEN 1.12 - 1,471 1,648
LEE MICHAEL STEWART 1.12 - 828 927
REDMILE GROUP, LLC 1.12 - 828 927
THOMPSON ELIZABETH H.Z. 1.12 - 694 777
TOPSOE CHRISTINA TENG 1.12 - 1,284 1,438
TOPSOE JAKOB HALDOR 1.12 - 828 927
Aggregate Net Quantity 7,839
Aggregate Net Value ($) 8,780
Aggregate Avg. Buy ($) 1.12
Aggregate Avg. Sell ($) -
Name Holder Date Type Quantity Price Value ($)
REDMILE GROUP, LLC Director 30 Jun 2025 Acquired (+) 828 1.12 927
LEE MICHAEL STEWART Director 30 Jun 2025 Acquired (+) 828 1.12 927
BAKER BROS. ADVISORS LP Director 30 Jun 2025 Acquired (+) 1,906 1.12 2,135
BEHRENS M KATHLEEN Director 30 Jun 2025 Acquired (+) 1,471 1.12 1,648
THOMPSON ELIZABETH H.Z. Director 30 Jun 2025 Acquired (+) 694 1.12 777
TOPSOE CHRISTINA TENG Director 30 Jun 2025 Acquired (+) 1,284 1.12 1,438
TOPSOE JAKOB HALDOR Director 30 Jun 2025 Acquired (+) 828 1.12 927

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria